Dr Reddys Laboratories annual ebitda
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dr Reddys Laboratories EBITDA Growth & History (RDY)
Dr Reddys Laboratories's calculated EBITDA was ₹88.90B for fiscal 2025.
View full Dr Reddys Laboratories company overviewDr Reddys Laboratories annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | ₹88.90B | ₹6.33B | +7.67% |
| 2024 | 2024-03-31 | ₹82.57B | ₹12.79B | +18.33% |
| 2023 | 2023-03-31 | ₹69.78B | ₹28.48B | +68.96% |
| 2022 | 2022-03-31 | ₹41.30B | ₹4.22B | +11.39% |
| 2021 | 2021-03-31 | ₹37.08B | ₹8.61B | +30.25% |
| 2020 | 2020-03-31 | ₹28.46B | −₹4.61B | −13.95% |
| 2019 | 2019-03-31 | ₹33.08B | ₹9.45B | +40.00% |
| 2018 | 2018-03-31 | ₹23.63B | −₹1.15B | −4.63% |
| 2017 | 2017-03-31 | ₹24.77B | −₹15.09B | −37.86% |
| 2016 | 2016-03-31 | ₹39.87B | — | — |
Dr Reddys Laboratories quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Dr Reddys Laboratories ebitda trends
Over the last five reported fiscal years, Dr Reddys Laboratories's ebitda increased from ₹28.46B to ₹88.90B, a change of ₹60.44B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dr Reddys Laboratories filings at SEC.gov ↗